Metachromatic leukodystrophy is a rare genetic condition where fatty substances accumulate in nerve cells, causing progressive loss of physical and mental abilities. While there is currently no cure, emerging therapies and supportive care approaches aim to slow disease progression and maintain quality of life for as long as possible.

Approaches to managing a challenging condition

When a child or adult receives a diagnosis of metachromatic leukodystrophy, families face difficult questions about what treatments exist and what can be done to help. The main goals of treatment focus on preserving neurological function, managing symptoms as they develop, and maintaining the best possible quality of life. Because this condition affects the protective covering around nerves called myelin, treatment strategies aim either to supply the missing enzyme that normally prevents damage, or to address the complications that arise when myelin breaks down.^[1]

The treatment approach depends heavily on which form of the disease a person has and how advanced their symptoms are at the time of diagnosis. Late infantile metachromatic leukodystrophy, which typically appears between 12 and 20 months of age, progresses rapidly and presents the greatest treatment challenges. Juvenile forms, appearing between ages 3 and 10, and adult forms, beginning after age 16, tend to progress more slowly and may respond differently to intervention.^[2]

Standard treatments approved by medical societies exist for certain patient groups, particularly those identified before symptoms begin or in very early stages. At the same time, researchers worldwide are investigating innovative therapies through clinical trials, offering hope that future treatments may be more effective and accessible to more patients.^[3]

Traditional medical approaches and supportive care

Currently, no treatment can reverse the nerve damage that metachromatic leukodystrophy causes. Instead, standard medical care focuses on managing symptoms and slowing disease progression when possible. For many patients, particularly those diagnosed after symptoms have already appeared, supportive care remains the primary treatment strategy.^[10]

Supportive care encompasses a wide range of interventions tailored to each patient’s specific needs. This includes medications to control seizures when they occur, as many children and adults with metachromatic leukodystrophy develop epilepsy as the disease progresses. Anti-epileptic drugs are selected based on seizure type and individual response.^[13]

When muscle stiffness becomes a problem, anti-spastic treatments help reduce rigidity and improve comfort. In severe cases, a medication called baclofen can be delivered directly into the fluid surrounding the spinal cord through a small pump implanted under the skin. This intrathecal delivery allows the medication to work more effectively while causing fewer side effects than oral medications.^[13]

Feeding difficulties are common as the disease affects the muscles involved in swallowing. When a person can no longer safely eat and drink by mouth, a feeding tube may be placed directly into the stomach through the abdominal wall. This ensures adequate nutrition and hydration while preventing dangerous food or liquid from entering the lungs.^[13]

Physical therapy and occupational therapy play crucial roles throughout the disease course. These therapies help maintain muscle strength and flexibility for as long as possible, support balance and coordination, and teach adaptive strategies for daily activities. Regular exercise programs tailored to individual abilities can help preserve mobility and independence.^[15]

Some patients develop gallbladder problems due to sulfatide accumulation in that organ. When this causes symptoms, surgical removal of the gallbladder through a minimally invasive procedure called laparoscopic cholecystectomy may be necessary.^[13]

Bone marrow and stem cell transplantation

For certain patients identified before symptoms appear or in very early disease stages, allogeneic hematopoietic stem cell transplantation represents a standard treatment option. This procedure involves replacing a patient’s blood-forming stem cells with healthy cells from a matched donor. The donor cells can come from bone marrow, peripheral blood, or umbilical cord blood.^[10]

The transplanted cells travel throughout the body, including into the brain and spinal cord, where they gradually replace the patient’s own cells that lack the necessary enzyme. Over time, the donor cells produce the missing enzyme called arylsulfatase A, which helps break down the fatty sulfatide molecules that cause damage.^[13]

However, this process takes considerable time—typically between 12 and 24 months before the disease stabilizes. During this waiting period, the patient’s condition may continue to worsen. The transplant procedure itself requires intensive preparation, including strong chemotherapy drugs to eliminate the patient’s existing bone marrow to make room for donor cells. This conditioning process can be difficult and carries risks.^[10]

Stem cell transplantation works best for patients with juvenile or adult forms of metachromatic leukodystrophy who are identified before symptoms begin or who have only mild symptoms. For these individuals, transplantation can provide clinical benefit and prolong survival. Unfortunately, this approach is not suitable for patients with late infantile disease, which progresses too rapidly for the donor cells to take effect before severe damage occurs.^[13]

The transplantation procedure carries significant risks, including infection, rejection of the donor cells, and graft-versus-host disease, where the donor cells attack the patient’s tissues. Because of these serious potential complications, doctors carefully evaluate each patient to determine whether the potential benefits outweigh the risks. Detailed testing of neurological function, developmental abilities, and organ systems is performed before proceeding.^[10]

Despite its limitations and risks, bone marrow transplantation has helped some patients with juvenile and adult metachromatic leukodystrophy maintain stable function for many years. In the United Kingdom and United States, some patients who received transplants have shown little or no further deterioration after 25 years.^[14]

Innovative therapies being tested in clinical trials

Researchers are actively investigating several promising new approaches to treating metachromatic leukodystrophy. These experimental therapies aim to address the underlying enzyme deficiency more directly and potentially offer benefits to patients who cannot be helped by current standard treatments.^[12]

Gene therapy: Correcting the genetic defect

Gene therapy represents one of the most exciting developments in metachromatic leukodystrophy treatment. This approach uses a modified virus called a lentiviral vector to insert a working copy of the ARSA gene into a patient’s own blood stem cells. The modified cells are then returned to the patient’s body, where they produce high levels of the missing enzyme.^[13]

Unlike donor stem cell transplantation, gene therapy uses the patient’s own cells, eliminating the risk of rejection or graft-versus-host disease. The genetically modified cells produce much more enzyme than normal cells, potentially providing faster and greater clinical benefit.^[13]

Clinical trials of gene therapy have shown promising results for children with late infantile and juvenile metachromatic leukodystrophy who are treated before symptoms begin or in very early disease stages. In December 2020, the European Medicines Agency approved a gene therapy product called Libmeldy for treating pre-symptomatic children with late infantile and early juvenile forms of the disease. This marked an important milestone as the first approved therapy specifically targeting the cause of metachromatic leukodystrophy.^[13]

In 2024, the United States Food and Drug Administration approved LENMELDY (atidarsagene autotemcel) as a one-time gene therapy for certain patients with metachromatic leukodystrophy. This represents a customized treatment where the patient’s own cells are genetically modified and returned to their body.^[7]

Current gene therapy trials are investigating whether this approach can benefit patients with late juvenile forms of the disease. These studies are being conducted at specialized centers, including the Ospedale San Raffaele in Milan, Italy, where the company Orchard Therapeutics is leading the research.^[13]

While early results from gene therapy trials have been encouraging, showing stable transgene expression and improved clinical outcomes, long-term safety and effectiveness beyond 15 years still need to be established. Additionally, the therapy is not yet available for patients with later disease onset or those with more advanced symptoms.^[13]

Enzyme replacement therapy delivered to the brain

Another innovative approach being tested involves delivering the missing enzyme directly into the fluid surrounding the brain and spinal cord. This method, called intrathecal enzyme replacement therapy, bypasses the challenge of getting enzymes from the bloodstream across the protective barrier that normally shields the brain.^[13]

In this experimental treatment, a laboratory-manufactured version of human arylsulfatase A enzyme is injected directly into the cerebrospinal fluid through the lower back, similar to a spinal tap. The enzyme then circulates throughout the nervous system, where it can potentially break down accumulated sulfatides and prevent further damage.^[13]

Phase 1 and Phase 2 clinical trials of intrathecal enzyme replacement therapy have been conducted to evaluate safety and dosing. Initial results showed that the treatment appears safe in the short term, though longer-term studies are needed to determine whether it provides meaningful clinical benefits. The company Takeda Pharmaceutical (formerly Shire) has been developing this approach, with planned trials at centers including Bristol Royal Hospital for Children in the United Kingdom.^[14]

This therapy is being investigated primarily for children with symptomatic late infantile metachromatic leukodystrophy, a group that currently has very limited treatment options. Trials have recruited both pre-symptomatic and symptomatic children who have not previously received other treatments like stem cell transplantation or gene therapy.^[14]

As of recent updates, intrathecal enzyme replacement therapy trials were not actively recruiting new participants, though research continues. Scientists are working to establish whether repeated enzyme injections can slow disease progression and improve quality of life for patients.^[13]

Other research directions

Scientists are exploring additional therapeutic strategies that may one day benefit patients with metachromatic leukodystrophy. Substrate reduction therapy takes a different approach by attempting to reduce the production of sulfatides rather than increasing enzyme activity. The theory is that if less substrate accumulates, less damage will occur even without full enzyme replacement.^[14]

Researchers are also conducting natural history studies to better understand how the disease progresses over time in different patient populations. These studies collect detailed information about symptoms, disease course, and outcomes, which helps scientists design better clinical trials and identify the most promising times to intervene with treatment.^[8]

International research collaborations are working to establish standardized outcome measures and clinical standards for evaluating treatments. This coordination helps ensure that results from different clinical trials can be meaningfully compared and that patients everywhere benefit from research advances.^[12]

Most common treatment methods

• Supportive and symptomatic care
  • Anti-epileptic medications for seizure control
  • Anti-spastic treatments including intrathecal baclofen for muscle rigidity
  • Feeding tube placement for nutrition when swallowing becomes difficult
  • Physical and occupational therapy to maintain mobility and daily living skills
  • Psychological and social support for patients and families
  • Laparoscopic cholecystectomy for gallbladder complications
• Hematopoietic stem cell transplantation
  • Allogeneic transplant using bone marrow, peripheral blood, or umbilical cord blood from healthy donors
  • Myeloablative conditioning with fludarabine and busulfan to prepare for transplant
  • Standard treatment for pre-symptomatic or early-symptomatic juvenile and adult patients
  • Donor cells migrate to brain and produce missing arylsulfatase A enzyme over 12-24 months
• Gene therapy
  • Autologous stem cell gene therapy using lentiviral vector with healthy ARSA gene copy
  • Libmeldy approved in Europe for pre-symptomatic late infantile and early juvenile patients
  • LENMELDY approved in United States as one-time customized treatment
  • Ongoing trials investigating use in late juvenile patients in Milan, Italy
  • Modified cells produce higher enzyme levels than normal cells for greater benefit
• Intrathecal enzyme replacement therapy
  • Direct injection of recombinant human arylsulfatase A into cerebrospinal fluid
  • Phase 1/2 trials showed short-term safety profile
  • Being investigated for symptomatic late infantile patients
  • Developed by Takeda Pharmaceutical Company
  • Trials planned at centers including Bristol Royal Hospital for Children